Dolinnov develops a first-in-class non-opioid therapy for chronic pain, one of the largest unmet medical needs worldwide. Despite recent progress, current approaches targeting single ion channels (Nav1.7, Nav1.8) face key limitations due to redundancy, as other channels can compensate over time, limiting long-term efficacy.

Dolinnov addresses this challenge by targeting a novel and highly differentiated peripheral mechanism. Instead of blocking ion channels, Dolinnov modulates a key regulator of neuronal excitability using lipid-conjugated antisense oligonucleotide (L-ASO) technology to selectively target the dorsal root ganglion (DRG), where chronic pain originates.

This approach enables the reduction of pathological nerve activity while preserving normal sensory function. Dolinnov’s lead candidate, DOL-001, has demonstrated strong efficacy across multiple in vivo pain models, with a long-lasting effect and robust translational potential supported by human DRG expression and mechanistic data.

By targeting ion pumps rather than ion channels, Dolinnov offers a precise, peripheral, non-opioid alternative that avoids central nervous system toxicity and overcomes the limitations of current analgesics.

MABQI is a biotech company specializing in the discovery and development of next-generation innovative antibodies and immunotherapies.

Its LiteMab© Antibody Discovery Studio integrates a suite of synthetic fully human libraries with an AI-powered display platform. The innovative LiteMab Sense platform specializes in pH-sensitive binders, optimizing therapeutic safety and efficacy by activating selectively in tumor or acidic microenvironments.

MABQI is advancing a targeted oncology pipeline leveraging its LiteMab© platform, featuring first-in-class and best-in-class highly developable antibodies- some with pH-sensitive features—spanning antibody-drug conjugates (ADCs), multispecific antibodies, and T-cell engagers to address critical unmet needs in solid and hematological tumors.

MABQI also welcomes research collaborations with biopharma partners on antibody discovery and maturation programs.

Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to discovering treatments for resistant and metastatic cancers.

OPM currently has two kinase inhibitors preparing for Phase 2 clinical development in patients: OPM-101, a RIPK2 inhibitor, has demonstrated a significant therapeutic margin and absence of toxicity in its Phase 1 healthy volunteer study. The compound is ready to start a Phase 1b/2a study in a few months, aiming to reverse resistance in advanced melanoma patients not responding or no longer responding to PD-1 checkpoint inhibitors. OPM’s RIPK2 inhibitors also hold significant potential in inflammatory diseases (IBD).

OPM-201, a LRRK2 inhibitor for Parkinson’s disease, completed its Phase 1 trial in healthy volunteers at the end of 2024. The compound is preparing for a Phase 1b/2 study in patients with LRRK2 genetic variants in Q1 2027. Ongoing CMC and toxicology work is fully funded by a grant award from The Michael J. Fox Foundation (MJFF), representing a major validation of the compound by MJFF experts. For both OPM-101 and OPM-201, the company is looking for partners and investors.

Both molecules come from OPM’s proprietary Nanocyclix® medicinal chemistry technology, which enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors. The platform is AI-assisted and consists of a highly annotated database and over 12,000 molecules. Multiple highly potent and selective inhibitor lead compounds are available for partnering.

OPM’s other two technology platforms are:
– OncoSNIPER, for the selection of therapeutic targets using artificial intelligence,
– PROMETHE® for the design and selection of radiolabeled theranostic molecules for systemic radiotherapy.
OPM, co-founded by Philippe Genne, Jan Hoflack and Karine Lignel, is based in Dijon, at the heart of the university and hospital cluster, and employs 14 people.

InSpek is a biotools company redefining bioprocess manufacturing through real-time monitoring and artificial intelligence. Its bioprocess optimization platform doesn’t just analyse data — it collects it, thanks to proprietary photonic sensing technology developed at MIT and CNRS. On-chip optical sensors capture rich, multimodal process data at any scale, directly within bioreactors, without sampling and without contamination risk. This fuels AI and chemometric models that learn process dynamics, detect anomalies, and identify optimal operating conditions — enabling higher yields, lower costs, and faster scale-up.

At the core of InSpek’s platform is MultiSpek: a single disposable microchip integrating Raman spectroscopy, pH, dissolved oxygen, temperature, and optical density sensing onto one photonic integrated circuit. Paired with a reusable control unit and intelligent software, the system delivers continuous, label-free, in-line analysis of critical process parameters — from metabolite concentrations to cell density — replacing slow, costly offline methods like HPLC. Designed for seamless integration into both single-use and stainless-steel bioreactors, MultiSpek supports upstream and downstream process intensification from early R&D through full-scale production.

This shift from batch-based sampling to fully continuous monitoring empowers pharmaceutical, biotech, and food-tech manufacturers to optimize yields, ensure consistent product quality, and accelerate process development — while reducing costs, resource consumption, and environmental impact. InSpek’s technology drives the transition toward smart, data-centric biomanufacturing in compliance with PAT frameworks, and Biomanufacturing 4.0.

Founded in 1995, Covalab is a French biotechnology company renowned for its expertise in antibody engineering. With over three decades of experience, Covalab specializes in the design and development of a wide range of antibodies, including polyclonal, monoclonal, scFv, Fab, VHH, and recombinant antibodies, utilizing advanced techniques such as DNA immunization.

Covalab’s DNA immunization technology provides a distinctive advantage in creating enhanced biological antibodies due to its capability to identify conformational epitopes, including challenging molecules such as transmembrane receptors with post-translational modifications. Covalab has successfully developed more than 20 superior biological antibodies, including those targeting TROP-2, PD-L1, and Nectin-4, which are available for out-licensing for Antibody-Drug Conjugate (ADC) applications.

Covalab’s comprehensive approach includes careful immunogen and animal host selection, rigorous screening processes, and state-of-the-art characterization. Committed to quality, the company holds ISO 9001:2015 certification, reflecting its dedication to excellence in services, products, and R&D.

Antelope Therapeutics is a preclinical-stage oncology company developing ATL-024, a novel Antibody-Drug Conjugate (ADC) against a first-in-class target for the treatment of colorectal and pancreatic cancers. These two diseases cause nearly 400,000 deaths annually across the 7MM and represent a multi-billion-dollar market opportunity.

Founded by ADC experts, including the former co-founder and CSO, and the former CBO of Mablink Bioscience (acquired by Eli Lilly), Antelope has identified CA242, a target with high expression prevalence across CRC and PDAC, representing 240,000+ patients annually, while being absent from healthy tissues.

ATL-024 combines a clinically de-risked antibody with an innovative proprietary linker platform and a topoisomerase I inhibitor payload to address this target. Preclinical studies have demonstrated compelling efficacy across multiple tumor models and an outstanding tolerability profile in NHP, supporting its best-in-disease potential.

Antelope is targeting clinical entry in 2027 and is seeking investors and partners to accelerate the development of ATL-024, including financing, licensing, and broader strategic discussions.